SAN FRANCISCO, Sept. 27, 2016 /PRNewswire/ -- Nektar
Therapeutics (Nasdaq: NKTR) announced that it will host a
conference call to discuss today's announcement of the new clinical
collaboration with Bristol-Myers Squibb. The call will begin at
9:00 a.m. Eastern Time
(ET)/6:00 a.m. Pacific Time (PT) on
Tuesday, September 27, 2016. A
live audio-only Webcast of the conference call can be accessed
through a link that is posted on the home page and Investor
Relations section of the Nektar website at http://www.nektar.com. A
webcast replay of the conference call will be available through
Friday, October 14, 2016.
To access the conference call, follow these instructions:
Dial: (877) 881-2183 (U.S.); (970) 315-0453 (international)
Passcode: 86947111 (Nektar Therapeutics is the host)
About Nektar
Nektar Therapeutics has a
robust R&D pipeline and portfolio of approved partnered
medicines in oncology, pain, immunology and other therapeutic
areas. In the area of oncology, Nektar is developing
NKTR-214, an immuno-stimulatory CD122-biased agonist, which is in
Phase 1/2 clinical development for patients with solid tumors.
ONZEALD™ (etirinotecan pegol), a long-acting topoisomerase I
inhibitor, is being developed for patients with advanced breast
cancer and brain metastases and is partnered with Daiichi Sankyo in
Europe. In the area of pain, Nektar has an
exclusive worldwide license agreement with AstraZeneca for
MOVANTIK™ (naloxegol), the first FDA-approved once-daily oral
peripherally-acting mu-opioid receptor antagonist (PAMORA)
medication for the treatment of opioid-induced constipation (OIC),
in adult patients with chronic, non-cancer pain. The product is
also approved in the European Union as MOVENTIG®
(naloxegol) and is indicated for adult patients with OIC who have
had an inadequate response to laxatives. The AstraZeneca agreement
also includes NKTR-119, an earlier stage development program that
is a co-formulation of MOVANTIK and an opioid. NKTR-181, a wholly
owned mu-opioid analgesic molecule for chronic pain conditions, is
in Phase 3 development. In hemophilia, Nektar has a
collaboration agreement with Baxalta for ADYNOVATE™ [Antihemophilic
Factor (Recombinant)], a longer-acting PEGylated Factor VIII
therapeutic approved in the U.S. andJapan for
patients over 12 with hemophilia A. In anti-infectives, the company
has two collaborations with Bayer Healthcare, Cipro Inhale in
Phase 3 for non-cystic fibrosis bronchiectasis and Amikacin Inhale
in Phase 3 for patients with Gram-negative pneumonia.
Nektar's technology has enabled nine approved products in
the U.S. or Europe through partnerships with
leading biopharmaceutical companies, including AstraZeneca's
MOVANTIK™, Baxalta's ADYNOVATE™, UCB's Cimzia® for Crohn's disease
and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and
Amgen's Neulasta® for neutropenia.
Nektar is headquartered in San Francisco, California, with additional operations
in Huntsville, Alabama and Hyderabad, India. Further information about the company
and its drug development programs and capabilities may be found
online at http://www.nektar.com.
MOVANTIK™ is a trademark and MOVENTIG® is a registered trademark
of the AstraZeneca group of companies. ADYNOVATE™ is a
trademark of Baxalta Inc.
ONZEALD™ is a trademark of Nektar Therapeutics.
Contact:
For Investors and Media:
Jennifer Ruddock of Nektar
Therapeutics
415-482-5585
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nektar-therapeutics-to-host-investor--analyst-conference-call-to-discuss-new-clinical-collaboration-with-bristol-myers-squibb-300334703.html
SOURCE Nektar Therapeutics